Molbio Diagnostics IPO: Rs 950 Cr Issue Opens Aug 10

Molbio Diagnostics is set to raise up to Rs 950.03 crore through its initial public offering. The 100% book-building issue will open for subscription on August 10, 2026, closing two days later on August 12, 2026.

IPO Key Figures

• Issue Size: Up to Rs 950.03 crore
• Total Shares: 1,17,72,311
• Face Value: Rs 1 per share
• Price Band: Rs 768-807 per equity share

The shares from this offering will be listed on both the BSE and NSE.

Investor Allocation Breakdown

The IPO structure includes specific allocations for different investor categories.

• Qualified Institutional Buyers (QIBs): Not more than 50% (5% reserved for mutual funds)
• Non-institutional Bidders: Not less than 15%
• Retail Investors: The remaining 35%

Molbio Diagnostics operates as an innovative point-of-care (POC) diagnostics company. Its focus is on expanding access to accurate, rapid, and cost-effective healthcare technologies for both infectious and non-communicable diseases.

About Molbio’s Truenat Platform

The company developed the ‘Truenat’ platform, a novel POC polymerase chain reaction (PCR) system. This platform is battery-operated, allowing for decentralized diagnosis within an hour, even in resource-limited settings.

• Patented in over 100 countries for diagnosing multiple diseases.
• Offers molecular testing for 30 diseases, including tuberculosis (TB), COVID, Hepatitis B and C, Human immunodeficiency virus (HIV), and Human Papillomavirus (HPV).
• Features 43 assays for these diagnostics.

Molbio Diagnostics operates within an oligopolistic market characterized by high entry barriers. Its platform underwent 13 years of Research and Development to secure Indian Council of Medical Research (ICMR) certification.

Notably, its ‘Truenat’ test chip for diagnosing TB is the sole offering by an Indian company and one of only two rapid molecular tests globally endorsed by the World Health Organization (WHO) for initial TB diagnosis and rifampicin resistance detection using molecular diagnostic technology.

The issue’s book running lead managers include Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors. Darshan Raghunath Karekar serves as the compliance officer for the offering.